Advertisement
AMGN vs LLY
Which Stock Would AI Choose? Amgen (AMGN) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- AMGN trades at a lower P/E ratio (price-to-earnings) of approximately 24 versus LLY's 38, suggesting better relative valuation.
- LLY commands a much larger market capitalization of $776 billion compared to AMGN's $183 billion, reflecting its growth premium.
- Both stocks have seen modest pullbacks of 2-3% over recent weeks amid broader market activity, with upcoming quarterly earnings as a shared catalyst.
- AMGN year-to-date (YTD) performance stands at around 4% positive, outperforming LLY's approximate 19% decline.
- AMGN offers a higher dividend yield near 3%, attracting income-oriented investors, while LLY's is about 0.7%.
- Technical indicators for AMGN remain neutral, with potential bullish patterns emerging in recent market positioning.
Introduction
This stock comparison pits AMGN, a mature biotechnology stalwart known for its stable dividend and diversified biologics portfolio, against LLY, a high-growth pharmaceutical powerhouse fueled by blockbuster weight-loss and diabetes treatments. Investors balancing value and growth in the healthcare sector, particularly those eyeing relative performance amid recent market volatility, will find value here. Traders monitoring biotech momentum, upcoming earnings catalysts, and sector sentiment shifts can use this analysis to gauge positioning between these two leaders in drug innovation and market share dynamics.
AMGN Overview and Recent Performance
Amgen (AMGN) is a leading biotechnology company specializing in human therapeutics, with key focuses on inflammation, oncology, and rare diseases through innovative biologics. In recent weeks, AMGN shares have experienced mild downward pressure, trading around $340 amid anticipation for first-quarter earnings. This pullback aligns with broader market activity, influenced by analyst previews projecting stable revenue growth and updates on pipeline assets like the experimental obesity drug MariTide. Sentiment remains steady, bolstered by a low beta of 0.47 indicating lower volatility, robust operating margins near 25%, and a consistent dividend payout, supporting its appeal as a defensive play in biotech.
LLY Overview and Recent Performance
Eli Lilly (LLY) is a global pharmaceutical giant propelled by diabetes and obesity drugs such as Mounjaro and Zepbound, alongside expansions in oncology and immunology. Over recent trading sessions, LLY shares have dipped around 2%, hovering near $868, reflecting short-term volatility from softer prescription data for its weight-loss portfolio and competitive pressures. Positive offsets include strategic acquisitions like Ajax Therapeutics to bolster hematology and partnerships in AI-driven genetic medicines. With a beta of 0.50 and higher revenue trajectory, sentiment mixes caution on near-term hurdles with optimism for long-term catalysts ahead of quarterly results.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available models that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from short-term scalping on 5-minute charts to longer-term trend following—displaying key stats like win rates often exceeding 60%, average returns ranging from 10-50% annualized in backtests, and profit factors above 1.5. Selected for current market conditions, including volatility levels (low to high), they cater to various styles with real-time signals for copy trading via signal, virtual, or brokerage agents. This dynamic section highlights bots outperforming benchmarks in promising sectors, offering traders data-driven edges without minimum balances on basic plans. Explore Trending AI Robots to identify suitable automated strategies today.
Head-to-Head Comparison
AMGN and LLY both anchor the biotech sector but diverge in business models: Amgen emphasizes mature, high-margin biologics with steady cash flows, while Eli Lilly pursues aggressive growth via GLP-1 agonists and M&A (mergers and acquisitions). Growth drivers contrast sharply—LLY's revenue has surged on obesity demand versus AMGN's more modest expansion—yet recent momentum favors AMGN's outperformance over the past year at 30% returns against LLY's 13%. Risk factors include patent cliffs and biosimilar competition for both, though LLY faces heightened scrutiny on drug uptake. Market sentiment tilts stable for AMGN (Hold rating) amid its dividend strength, while LLY trades at a premium on growth prospects but with elevated volatility.
Tickeron AI Verdict
Tickeron’s AI tools, analyzing trend consistency, valuation metrics, and relative stability, currently favor AMGN over LLY. Factors include its cheaper P/E, superior recent relative performance, lower volatility (beta 0.47), and attractive yield, positioning it probabilistically stronger in the near-term market environment ahead of earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and LLY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 7 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 3 bearish.
- LLY’s TA Score: 7 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.17% price change this week, while LLY (@Pharmaceuticals: Major) price change was +3.26% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.94%. For the same industry, the average monthly price growth was -2.11%, and the average quarterly price growth was +2.39%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
LLY is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.94% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | LLY | AMGN / LLY | |
| Capitalization | 182B | 898B | 20% |
| EBITDA | 16.7B | 36.2B | 46% |
| Gain YTD | 3.437 | -6.169 | -56% |
| P/E Ratio | 23.40 | 35.76 | 65% |
| Revenue | 37.2B | 72.2B | 52% |
| Total Cash | 12B | 5.28B | 227% |
| Total Debt | 57.3B | 43.4B | 132% |
AMGN | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 17 Undervalued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 33 | 17 | |
SMR RATING 1..100 | 13 | 13 | |
PRICE GROWTH RATING 1..100 | 55 | 48 | |
P/E GROWTH RATING 1..100 | 52 | 87 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (17) in the Biotechnology industry is in the same range as LLY (40) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (17) in the Pharmaceuticals Major industry is in the same range as AMGN (33) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
LLY's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as AMGN (13) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
LLY's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as AMGN (55) in the Biotechnology industry. This means that LLY’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for LLY (87) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than LLY’s over the last 12 months.
| AMGN | LLY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 53% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 58% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 50% | 2 days ago 68% |
| Advances ODDS (%) | 3 days ago 56% | 3 days ago 70% |
| Declines ODDS (%) | 12 days ago 51% | 8 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 52% | 2 days ago 60% |
Advertisement